Loading the security overview…
Where the tokens are
None held
3 tokenized versions from 3 issuers
See every versionNo venues yet
No vault or pool we index takes these tokens.
PerpsNo markets
No Hyperliquid venue lists a REGN perp.
Where the tokens are
Key statistics
technicals as of Oct 2, 2026- Market cap
- $75.65B
- P/E
- 17.5EPS $42.04
- 52-week range
- $541.00 – $859.34price at 63% of range
- Volume
- 477.09Kaverage day 723.86K
- Previous close
- $734.81
- P/S
- 4.9
- P/B
- 2.4
- Dividend yield
- 0.50%$3.76 a year
- Next ex-dividend
- —
- Next earnings
- Oct 30before the open
- Beta
- 0.3690 days, against SPY
- RSI (14)
- 34.9as of Oct 2
Figures describe Regeneron Pharmaceuticals shares, not any token.
Every tokenized version
Search and filter all tokensEach row is one issuer’s token for Regeneron Pharmaceuticals, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.
About Regeneron Pharmaceuticals Inc
regeneron.comRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Type
- Common stock
- Sector
- Healthcare › Biotechnology
- Exchange
- Nasdaq
- Listed since
- Apr 2, 1991
- Shares outstanding
- 101.14M
- Employees
- 15,410
Themes
Biotech - Drug Development › Immunology & AutoimmuneHealthcare - Oncology › Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine › Gene Therapy & Gene Editing
Companies sharing these themesAs the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.
